Genentech, Inc.

Genetech, Inc.

Yvonne M Chen

Mark S Dennis

Andrew G Polson

Jagath Reddy Junutula

Kristi Elkins

Bing Zheng

David Dornan

Anan Chuntharapai

Terence Wong

Lawren Wu

Mercedesz Balazs

Hans Brightbill

Henry Bernard Lowman

Wenjun Ouyang

Andrew C Chan

Patricia Valdez

Yves Muller

Yan Zheng

Andy Chan

Jianfeng Wu

Susan Sa

Dimitry Danilenko

Jane Louise Grogan

Matthew Lawrence Albert

Simon-Peter Williams

Eugene Yu-Chuan Chiang

Patricia Waldez

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Humanized anti-CD79B antibodies and immunoconjugates and methods of use

Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.

Anti-CD8 antibodies and uses thereof

The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.

Anti-CD79B antibodies and immunoconjugates and methods of use

Humanized anti-CD79b antibodies and immunoconjugates and methods of use

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals, including immunoconjugates comprising anti-CD79b cysteine-engineered antibody huMA79b.v28, and to methods of using those compositions of matter for the same.

The present invention is directed to anti-CD79b antibodies with specific hypervariable region sequences in the heavy and light chain variable domains as enumerated in the SEQ ID NOs described herein.

Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.

Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling

The present invention is directed to cysteine-engineered anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.

Antibody variants

The present invention is directed to compositions of matter comprising nucleic acids encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 207 or 208, encoding an anti-CD79b antibody comprising the heavy chain variable domain sequence of SEQ ID NO: 207 and the light chain variable domain sequence of SEQ ID NO: 208, or encoding an anti-CD79b antibody having : (i) a variable light chain comprising a HVR-L1 having the sequence of SEQ ID NO: 194, a HVR-L2 having the sequence of SEQ ID NO: 195, and a HVR-L3 having the sequence of SEQ ID NO: 196 and (ii) a variable light chain comprising a HVR-H1 having the sequence of SEQ ID NO: 202, a HVR-H2 having the sequence of SEQ ID NO: 203, and a HVR-H3 having the sequence of SEQ ID NO: 204, and vectors and host cells thereof.

The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

Growing community of inventors

San Mateo, CA, United States of America

Yvonne M Chen